Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination
with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small
cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of
relapsed small cell lung cancer patients treated with this combination therapy. **The Phase
1b portion of the study is now complete**.
Phase 2 portion of the study. The safest, maximally tolerated dose established as established
in Phase 1 for Phase 2 is as follows -- Carfilzomib will be provided at 20/36 mg/m2 with
Irinotecan dosed at 125 mg/m2. The purpose of the Phase 2 portion of the study is to assess 6
month survival of relapsed small cell lung cancer ins subjects treated with this combination
therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cancer Research and Biostatistics Clinical Trials Consortium
Collaborators:
Lucille P. Markey Cancer Center at University of Kentucky Washington University School of Medicine